dRx Capital

What is dRx Capital?

dRx Capital is an investment fund based in the United States that specializes in funding early-stage companies operating in the digital health and pharma services IT sectors. Their focus predominantly lies within the range of Seed to Series B funding stages.

They stand out by committing significant capital to ventures that they believe have the potential to disrupt healthcare through innovative technological solutions. dRx Capital actively seeks opportunities to invest in companies that leverage technology to improve patient outcomes, optimize healthcare services, and streamline pharmaceutical operations.

With a minimum investment size of $4,000,000 and a maximum investment size of $6,000,000, they provide substantial financial backing to startups they decide to support. dRx Capital's investment thesis centers around backing teams with the potential to lead the digital transformation in health, aligning with their belief that technology can bring about a new era of personalized and efficient healthcare services.

The fund operates extensively in the United States and looks to forge strong partnerships with entrepreneurs who share their vision of advancing healthcare through innovative digital solutions. While they focus on Series A and beyond, their involvement in the Seed stage indicates a willingness to engage with companies from a relatively early point in their development cycle.

What they say:

Novartis dRx Capital backs exceptional entrepreneurs transforming healthcare through data and digital technology. The fund, backed by Novartis, invests in technology platforms improving access to healthcare and reimagining the practice of medicine, with a focus on AI & ML, R&D optimization, patient care, supply chain and commercialization.

What we look for: We invest in digital health, pharma services IT. Series A+.